AKT1 and acute myeloid leukemia: Regarding the mechanisms of Src-enhanced chemoresistance, Src confers to AKT/MTOR activation in acute myeloid leukemia for cancer stemness (Li et al., 2014), which is highly associated with drug resistance (Prieto-Vila et al., 2017).